Systematic review of L ‐glutamine for prevention of vaso‐occlusive pain crisis in patients with sickle cell disease
DiscussionL ‐glutamine has limited high‐quality evidence supporting its use. Although L‐glutamine is FDA approved for the prevention of frequent episodes of VOC pain, only one randomized controlled trial has strong evidence to support this indication. Based on the results of a systematic review, L‐gluta mine may be considered for patients unable to receive hydroxyurea or in addition to hydroxyurea for reduction in VOC and associated pain.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Timothy C. Hutcherson,
Nicole E. Cieri ‐Hutcherson,
Erin E. Conway‐Habes,
Brianna N. Burns,
Nathan A. White Tags: REVIEW OF THERAPEUTICS Source Type: research
More News: Burns | Drugs & Pharmacology | Food and Drug Administration (FDA) | Pain | Sickle Cell Anemia | Study | USA Health